Both US patients appear to be responding well to experimental drugs provided by San Diego-based Mapp Biopharmaceutical. The Company is manufacturing more of the drug, while conducting clinical trials. Larry Zeitlin, the president of Mapp:
It’s absolutely overwhelming. We are discussing with the F.D.A. the right path to make the drug available to people as quickly and safely as possible.
Major decisions on how and where the drug will go are being discussed. Dr. Whaley:
We definitely would like to ramp up to have an impact on the Ebola epidemic. We’re not decision makers on many of these issues. There are regulatory and legal issues that have to be addressed.